Stockscreener 앱 받기
17.03
0.65%
0.11
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Franklin Resources Inc. Trims Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $81.33 - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation - AccessWire
Keros Therapeutics, Inc. (NASDAQ:KROS) Stake Lowered by Y Intercept Hong Kong Ltd - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by State Street Corp - Defense World
(KROS) Investment Analysis and Advice - Stock Traders Daily
Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share - Seeking Alpha
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Keros Therapeutics: Hold Through The Dust - Seeking Alpha
Keros Therapeutics (NASDAQ:KROS) Shares Down 5.7% After Analyst Downgrade - Defense World
Keros Therapeutics (NASDAQ:KROS) Given New $63.00 Price Target at Oppenheimer - Defense World
Keros Therapeutics (NASDAQ:KROS) Trading Down 5.7% After Analyst Downgrade - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Shares Gap Down Following Analyst Downgrade - Defense World
Keros Therapeutics shares price target cut on ceased dosing By Investing.com - Investing.com Canada
Where Keros Therapeutics Stands With Analysts - Benzinga
Keros Therapeutics (NASDAQ:KROS) Shares Gap Down on Analyst Downgrade - MarketBeat
Oppenheimer Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $63.00 - MarketBeat
Guggenheim Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat
HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $47.00 - Defense World
Keros Stock Hits Rock Bottom After Pulmonary Hypertension Trial Halt, But Retail Bets On A Rebound - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Scotiabank Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Keros Therapeutics price target raised to $28 from $11 at Wells Fargo - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Investors to Inquire about Securities Investigation - AccessWire
Jefferies sees limited efficacy but keeps Keros Therapeutics stock at Buy - Investing.com
Blow For Keros’s PAH Candidate As Dreams Of Surpassing Winrevair Fade - Citeline
HC Wainwright Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
William Blair Downgrades Keros Therapeutics (KROS) - MSN
Traders Purchase High Volume of Keros Therapeutics Call Options (NASDAQ:KROS) - Defense World
TD Cowen Downgrades Keros Therapeutics (KROS) - MSN
TD Cowen cuts Keros Therapeutics stock to Hold on trial concerns - Investing.com Canada
Keros Therapeutics stock hits 52-week low at $18.63 By Investing.com - Investing.com South Africa
Keros Therapeutics shares downgraded to neutral by BTIG on clinical trial - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out - AccessWire
Keros stock plunges 73% on drug study halt over safety concerns (update) - MSN
Keros stock wilts as it halts two dosing arms in hypertension study - BioWorld Online
Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial - Reuters
Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead Drug - Yahoo! Voices
Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff (KROS) - Seeking Alpha
Lexington biotech's stock crashes after partial drug trial pause - The Business Journals
Keros Therapeutics stock hits 52-week low at $18.63 - Investing.com
Keros stock plunges 76% on drug study halt over safety concerns - MSN
Keros Therapeutics (NASDAQ:KROS) Downgraded to Hold Rating by TD Cowen - MarketBeat
Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Benzinga
Keros Thera slumps after halting parts of cibotercept trial - The Pharma Letter
Keros Therapeutics (NASDAQ:KROS) Lowered to "Market Perform" Rating by William Blair - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Downgraded by BTIG Research to "Neutral" - MarketBeat
Keros Therapeutics Loses 75% Value In A Single SessionHere's Why - Benzinga
Keros Therapeutics halts dosing of blood pressure treatment after safety review - MSN
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Keros Therapeutics halts dosing in trial after adverse events By Investing.com - Investing.com Nigeria
Keros Therapeutics halts dosing in trial after adverse events - Investing.com
Keros Plunges After Dosing Halted in Lung Drug Trial on Safety - BNN Bloomberg
Keros' stock tanks after halting 2 arms of hypertension trial over fluid buildups around heart - Fierce Biotech
Keros Therapeutics provides update on Phase 2 TROPOS trial - TipRanks
2.88%
2.65%
자본화:
|
볼륨(24시간):